Pierre-Emmanuel Morange

List of Publications by Year
in descending order

288	15,892	16451 64	21540 114
papers	citations	h-index	g-index

323	323	323	22561
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Human genetic and immunological determinants of critical COVID-19 pneumonia. Nature, 2022, 603, 587-598.	27.8	216
2	Is Oxidative Stress an Emerging Player in the Thrombosis of Patients with Anti-Phosphatidylethanolamine Autoantibodies?. Journal of Clinical Medicine, 2022, 11, 1297.	2.4	1
3	Elucidating mechanisms of genetic cross-disease associations at the PROCR vascular disease locus. Nature Communications, 2022, 13, 1222.	12.8	5
4	Multiâ€phenotype analyses of hemostatic traits with cardiovascular events reveal novel genetic associations. Journal of Thrombosis and Haemostasis, 2022, 20, 1331-1349.	3.8	12
5	Epimutations in both the TESK2 and MMACHC promoters in the Epi-cblC inherited disorder of intracellular metabolism of vitamin B12. Clinical Epigenetics, 2022, 14, 52.	4.1	10
6	Two SERPINC1 variants affecting N-glycosylation of Asn224 cause severe thrombophilia not detected by functional assays. Blood, 2022, 140, 140-151.	1.4	11
7	Management of bleeding risk in patients who receive anticoagulant therapy for venous thromboembolism: Communication from the ISTH SSC Subcommittee on Predictive and Diagnostic Variables in Thrombotic Disease. Journal of Thrombosis and Haemostasis, 2022, 20, 1910-1919.	3.8	12
8	Long-Read Sequencing Identifies the First Retrotransposon Insertion and Resolves Structural Variants Causing Antithrombin Deficiency. Thrombosis and Haemostasis, 2022, 122, 1369-1378.	3.4	9
9	Development and implementation of common data elements for venous thromboembolism research: on behalf of SSC Subcommittee on official Communication from the SSC of the ISTH. Journal of Thrombosis and Haemostasis, 2021, 19, 297-303.	3.8	27
10	A rare coding mutation in the MAST2 gene causes venous thrombosis in a French family with unexplained thrombophilia: The Breizh MAST2 Arg89Gln variant. PLoS Genetics, 2021, 17, e1009284.	3.5	2
11	Explainable Artificial Neural Network for Recurrent Venous Thromboembolism Based on Plasma Proteomics. Lecture Notes in Computer Science, 2021, , 108-121.	1.3	4
12	Clinical validation of immunoassay HemosILÂ® AcuStar HIT-IgG (PF4-H) in the diagnosis of Heparin-induced thrombocytopenia. Journal of Thrombosis and Thrombolysis, 2021, 52, 601-609.	2.1	5
13	Reply to Chen and Vitetta. Journal of Infectious Diseases, 2021, 223, 1660-1662.	4.0	1
14	<scp>CD169</scp> and <scp>CD64</scp> could help differentiate bacterial from <scp>CoVID</scp>â€19 or other viral infections in the Emergency Department. Cytometry Part A: the Journal of the International Society for Analytical Cytology, 2021, 99, 435-445.	1.5	28
15	Association between ABO haplotypes and the risk of venous thrombosis: impact on disease risk estimation. Blood, 2021, 137, 2394-2402.	1.4	19
16	Severe thrombophilia in a factor Vâ€deficient patient homozygous for the Ala2086Asp mutation (FV) Tj ETQq0 0 0 rgBT /Overlock 10 Tf	3.8	15
17	Impaired adhesion of neutrophils expressing Slc44a2/HNA-3b to VWF protects against NETosis under venous shear rates. Blood, 2021, 137, 2256-2266.	1.4	16
18	FGL1 as a modulator of plasma Dâ€dimer levels: Exomeâ€wide marker analysis of plasma tPA, PAIâ€1, and Dâ€dimer. Journal of Thrombosis and Haemostasis, 2021, 19, 2019-2028.	3.8	1

#	Article	IF	Citations
19	Heparinâ€induced thrombocytopenia: Construction of a pretest diagnostic score derived from the analysis of a prospective multinational database, with internal validation. Journal of Thrombosis and Haemostasis, 2021, 19, 1959-1972.	3.8	14
20	An artificial neural network approach integrating plasma proteomics and genetic data identifies PLXNA4 as a new susceptibility locus for pulmonary embolism. Scientific Reports, 2021, 11, 14015.	3.3	8
21	Cell Analysis from Dried Blood Spots: New Opportunities in Immunology, Hematology, and Infectious Diseases. Advanced Science, 2021, 8, e2100323.	11.2	7
22	PRDX1 gene-related epi-cblC disease is a common type of inborn error of cobalamin metabolism with mono- or bi-allelic MMACHC epimutations. Clinical Epigenetics, 2021, 13, 137.	4.1	6
23	GATA1 pathogenic variants disrupt MYH10 silencing during megakaryopoiesis. Journal of Thrombosis and Haemostasis, 2021, 19, 2287-2301.	3.8	6
24	The aminosterol Claramine inhibits Î²-secretase 1â€“mediated insulin receptor cleavage. Journal of Biological Chemistry, 2021, 297, 100818.	3.4	4
25	Single or triple positivity for antiphospholipid antibodies in â€œcarriersâ€•or symptomatic patients: Untangling the knot. Journal of Thrombosis and Haemostasis, 2021, 19, 3018-3030.	3.8	9
26	Genomic and phenotypic insights from an atlas of genetic effects on DNA methylation. Nature Genetics, 2021, 53, 1311-1321.	21.4	218
27	The EHA Research Roadmap: Blood Coagulation and Hemostatic Disorders. HemaSphere, 2021, 5, e643.	2.7	3
28	Direct freezing of whole blood enables analysis of leucocyte markers by flow cytometry: a proof-of-concept study. Future Microbiology, 2021, 16, 955-966.	2.0	0
29	Cerebral Venous Thrombosis: Clinical, Radiological, Biological, and Etiological Characteristics of a French Prospective Cohort (FPCCVT)â€”Comparison With ISCVT Cohort. Frontiers in Neurology, 2021, 12, 753110.	2.4	10
30	Toward Monocyte HLA-DR Bedside Monitoring: A Proof-of-Concept Study. Shock, 2021, 55, 782-789.	2.1	7
31	Lipoprotein(a): Pathophysiology, measurement, indication and treatment in cardiovascular disease. A consensus statement from the Nouvelle SociÃ©tÃ© Francophone dâ€™AthÃ©roscl Ã©rose (NSFA). Archives of Cardiovascular Diseases, 2021, 114, 828-847.	1.6	9
32	Interest of IgG and IgM antiprothrombin autoantibodies in the exploration of antiphospholipid syndrome: a 5-year retrospective study. Rheumatology, 2020, 59, 1539-1544.	1.9	4
33	High prevalence of mutations in perilipin 1 in patients with precocious acute coronary syndrome. Atherosclerosis, 2020, 293, 86-91.	0.8	2
34	A Combination of Single Nucleotide Polymorphisms is Associated with the Interindividual Variability of Cholesterol Bioavailability in Healthy Adult Males. Molecular Nutrition and Food Research, 2020, 64, 2000480.	3.3	3
35	Plasma Biomarkers and Identification of Resilient Metabolic Disruptions in Patients With Venous Thromboembolism Using a Metabolic Systems Approach. Arteriosclerosis, Thrombosis, and Vascular Biology, 2020, 40, 2527-2538.	2.4	21
36	Inborn errors of type I IFN immunity in patients with life-threatening COVID-19. Science, 2020, 370, .	12.6	1,749

#	Article	IF	Citations
37	A Granulocytic Signature Identifies COVID-19 and Its Severity. Journal of Infectious Diseases, 2020, 222, 1985-1996.	4.0	81
38	Ethnicity and Haemostasis: Challenge in the genomics era. Journal of Thrombosis and Haemostasis, 2020, 18, 1274-1275.	3.8	0
39	Bayesian network analysis of plasma microRNA sequencing data in patients with venous thrombosis. European Heart Journal Supplements, 2020, 22, C34-C45.	0.1	9
40	A Platelet Function Modulator of Thrombin Activation Is Causally Linked to Cardiovascular Disease and Affects PAR4 Receptor Signaling. American Journal of Human Genetics, 2020, 107, 211-221.	6.2	26
41	ABO blood group, glycosyltransferase activity and risk of venous thromboembolism. Thrombosis Research, 2020, 193, 31-35.	1.7	10
42	Flow cytometry evaluation of infection-related biomarkers in febrile subjects in the emergency department. Future Microbiology, 2020, 15, 189-201.	2.0	14
43	Role of the interferons in CD64 and CD169 expressions in whole blood: Relevance in the balance between viralâ€•or bacterialâ€oriented immune responses. Immunity, Inflammation and Disease, 2020, 8, 106-123.	2.7	40
44	SLC44A2 deficient mice have a reduced response in stenosis but not in hypercoagulability driven venous thrombosis. Journal of Thrombosis and Haemostasis, 2020, 18, 1714-1727.	3.8	18
45	A novel rare c.-39C>T mutation in the PROS1 5â€²UTR causing PS deficiency by creating a new upstream translation initiation codon. Clinical Science, 2020, 134, 1181-1190.	4.3	10
46	Dabigatran Level Before Reversal Can Predict Hemostatic Effectiveness of Idarucizumab in a Real-World Setting. Frontiers in Medicine, 2020, 7, 599626.	2.6	11
47	The Assistance Publique HÃ´pitaux de Marseilleâ€™s Biobank. Open Journal of Bioresources, 2020, 7, .	1.5	3
48	High-Dimensional Multi-Block Analysis of Factors Associated with Thrombin Generation Potential. , 2019, , .		1
49	Genomic and transcriptomic association studies identify 16 novel susceptibility loci for venous thromboembolism. Blood, 2019, 134, 1645-1657.	1.4	162
50	A Genome Wide Association Study on plasma FV levels identified PLXDC2 as a new modifier of the coagulation process. Journal of Thrombosis and Haemostasis, 2019, 17, 1808-1814.	3.8	6
51	Associations of autozygosity with a broad range of human phenotypes. Nature Communications, 2019, 10, 4957.	12.8	84
52	A largeâ€scale exome array analysis of venous thromboembolism. Genetic Epidemiology, 2019, 43, 449-457.	1.3	22
53	Common Risk Factors Add to Inherited Thrombophilia to Predict Venous Thromboembolism Risk in Families. TH Open, 2019, 03, e28-e35.	1.4	10
54	OPTIMIR, a novel algorithm for integrating available genome-wide genotype data into miRNA sequence alignment analysis. Rna, 2019, 25, 657-668.	3.5	7

#	Article	IF	Citations
55	Minor allele of the factor V K858R variant protects from venous thrombosis only in non-carriers of factor V Leiden mutation. Scientific Reports, 2019, 9, 3750.	3.3	7
56	Clinical research assessment by flow cytometry of biomarkers for infectious stratification in an Emergency Department. Biomarkers in Medicine, 2019, 13, 1373-1386.	1.4	19
57	Genome-Wide Association Transethnic Meta-Analyses Identifies Novel Associations Regulating Coagulation Factor VIII and von Willebrand Factor Plasma Levels. Circulation, 2019, 139, 620-635.	1.6	102
58	Intravenous immunoglobulin in patients with acquired Von Willebrand syndrome: A single referral centre experience. Haemophilia, 2019, 25, e42-e45.	2.1	3
59	Antithrombotic efficacy of bivalirudin compared to unfractionated heparin during percutaneous coronary intervention for acute coronary syndrome. Platelets, 2019, 30, 105-111.	2.3	3
60	Lean body weight is the best scale for venous thromboprophylaxis algorithm in severely obese patients undergoing bariatric surgery. Pharmacological Research, 2018, 131, 211-217.	7.1	7
61	Management of antiplatelet therapy in patients undergoing elective invasive procedures: Proposals from the French Working Group on perioperative hemostasis (GIHP) and the French Study Group on thrombosis and hemostasis (GFHT). In collaboration with the French Society for Anesthesia and Intensive Care (SFAR). Archives of Cardiovascular Diseases, 2018, 111, 210-223.	1.6	22
62	Management of antiplatelet therapy in patients undergoing elective invasive procedures. Proposals from the French Working Group on perioperative haemostasis (GIHP) and the French Study Group on thrombosis and haemostasis (GFHT). In collaboration with the French Society for Anaesthesia and Intensive Care Medicine (SFAR). Anaesthesia, Critical Care & Pain Medicine, 2018, 37, 379-389.	1.4	25
63	A PRDX1 mutant allele causes a MMACHC secondary epimutation in cblC patients. Nature Communications, 2018, 9, 67.	12.8	64
64	Initial strides for invent-VTE: Towards global collaboration to accelerate clinical research in venous thromboembolism. Thrombosis Research, 2018, 163, 128-131.	1.7	4
65	Position du GIHP sur les tests viscoÃ©lastiquesÂ: quelle place pour quelle indication en situation hÃ©morragiqueÂ?. AnesthÃ©sie & RÃ©animation, 2018, 4, 452-464.	0.1	0
66	What is currently known about the genetics of venous thromboembolism at the dawn of next generation sequencing technologies. British Journal of Haematology, 2018, 180, 335-345.	2.5	34
67	Assessment of platelet function on the routine coagulation analyzer Sysmex CS-2000i. Platelets, 2018, 29, 95-97.	2.3	17
68	The missing heritability of venous thrombosis: what about factorÂV Leiden heterogeneity?. Journal of Thrombosis and Haemostasis, 2018, 16, 2125-2127.	3.8	0
69	Human thymopoiesis is influenced by a common genetic variant within the TCRA-TCRD locus. Science Translational Medicine, 2018, 10, .	12.4	33
70	DNA methylation age is associated with an altered hemostatic profile in a multiethnic meta-analysis. Blood, 2018, 132, 1842-1850.	1.4	16
71	Abstract 090: Slc44a2 Deficient Mice Exhibit Less Severity of Thrombosis in a Stenosis Model of Deep Vein Thrombosis. Arteriosclerosis, Thrombosis, and Vascular Biology, 2018, 38, .	2.4	1
72	Genome-wide association study with additional genetic and post-transcriptional analyses reveals novel regulators of plasma factor XI levels. Human Molecular Genetics, 2017, 26, ddw401.	2.9	35

#	Article	IF	Citations
73	Germline variants in ETV6 underlie reduced platelet formation, platelet dysfunction and increased levels of circulating CD34 ⁺ progenitors. Haematologica, 2017, 102, 282-294.	3.5	70
74	Leveraging cell type specific regulatory regions to detect SNPs associated with tissue factor pathway inhibitor plasma levels. Genetic Epidemiology, 2017, 41, 455-466.	1.3	1
75	Management of Severe Bleeding in Patients Treated with Direct Oral Anticoagulants. Anesthesiology, 2017, 127, 111-120.	2.5	52
76	Benefit of switching dual antiplatelet therapy after acute coronary syndrome: the TOPIC (timing of) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 5 38, 3070-3078.	2.2	316
77	Direct oral anticoagulants and digestive bleeding: therapeutic management and preventive measures. Therapeutic Advances in Gastroenterology, 2017, 10, 495-505.	3.2	25
78	Assessing the causal relationship between obesity and venous thromboembolism through a Mendelian Randomization study. Human Genetics, 2017, 136, 897-902.	3.8	46
79	Protein S Heerlen mutation heterozygosity is associated with venous thrombosis risk. Scientific Reports, 2017, 7, 45507.	3.3	14
80	Macrothrombocytopenia and dense granule deficiency associated with FLI1 variants: ultrastructural and pathogenic features. Haematologica, 2017, 102, 1006-1016.	3.5	34
81	Homocysteine levels associate with subtle changes in leukocyte DNA methylation: an epigenome-wide analysis. Epigenomics, 2017, 9, 1403-1422.	2.1	6
82	Blood triglyceride levels are associated with DNA methylation at the serine metabolism gene PHGDH. Scientific Reports, 2017, 7, 11207.	3.3	32
83	The usefulness of infection biomarkers in patients with febrile neutropenia in the Emergency Department. Enfermedades Infecciosas Y Microbiologia Clinica (English Ed), 2017, 35, 395-396.	0.3	0
84	Perioperative thromboprophylaxis in severely obese patients undergoing bariatric surgery: insights from a French national survey. Surgery for Obesity and Related Diseases, 2017, 13, 320-326.	1.2	20
85	Genetic risk factors for venous thrombosis in women using combined oral contraceptives: update of the <scp>PILGRIM</scp> study. Clinical Genetics, 2017, 91, 131-136.	2.0	7
86	Benefit of Switching Dual Antiplatelet Therapy After Acute Coronary Syndrome According to On-Treatment Platelet Reactivity. JACC: Cardiovascular Interventions, 2017, 10, 2560-2570.	2.9	36
87	Peripartum bleeding management in a patient with Cal<scp>DAG</scp>â€<scp>GEFI</scp> deficiency. Haemophilia, 2017, 23, e533-e535.	2.1	5
88	Association of impaired renal function with venous thrombosis: A genetic risk score approach. Thrombosis Research, 2017, 158, 102-107.	1.7	2
89	Sex-specific effect of CPB2 Ala147Thr but not Thr325Ile variants on the risk of venous thrombosis: A comprehensive meta-analysis. PLoS ONE, 2017, 12, e0177768.	2.5	5
90	Genetically defined elevated homocysteine levels do not result in widespread changes of DNA methylation in leukocytes. PLoS ONE, 2017, 12, e0182472.	2.5	10

#	Article	IF	Citations
91	Risk factors for venous thromboembolism in women under combined oral contraceptive. Thrombosis and Haemostasis, 2016, 115, 135-142.	3.4	35
92	Is there still room for additional common susceptibility alleles for venous thromboembolism?. Journal of Thrombosis and Haemostasis, 2016, 14, 1798-1802.	3.8	12
93	Potential mechanism of acute stent thrombosis with bivalirudin following percutaneous coronary intervention in acute coronary syndromes. International Journal of Cardiology, 2016, 220, 496-500.	1.7	11
94	PDGFB, a new candidate plasma biomarker for venous thromboembolism: results from the VEREMA affinity proteomics study. Blood, 2016, 128, e59-e66.	1.4	39
95	Formyl Peptide Receptor 2 Plays a Deleterious Role During Influenza A Virus Infections. Journal of Infectious Diseases, 2016, 214, 237-247.	4.0	34
96	Single nucleotide polymorphisms in an intergenic chromosome 2q region associated with tissue factor pathway inhibitor plasma levels and venous thromboembolism. Journal of Thrombosis and Haemostasis, 2016, 14, 1960-1970.	3.8	3
97	Î±1-antitrypsin Pittsburgh and plasmin-mediated proteolysis. Journal of Thrombosis and Haemostasis, 2016, 14, 2023-2026.	3.8	4
98	Is platelet inhibition correlated with time from last intake on P2Y12 blockers after an acute coronary syndrome? A pilot study. Platelets, 2016, 27, 791-795.	2.3	1
99	The European Hematology Association Roadmap for European Hematology Research: a consensus document. Haematologica, 2016, 101, 115-208.	3.5	67
100	A meta-analysis of 120 246 individuals identifies 18 new loci for fibrinogen concentration. Human Molecular Genetics, 2016, 25, 358-370.	2.9	73
101	Argatroban in the management of heparin-induced thrombocytopenia: a multicenter clinical trial. Critical Care, 2015, 19, 396.	5.8	49
102	Genetics of Venous Thrombosis: update in 2015. Thrombosis and Haemostasis, 2015, 114, 910-919.	3.4	81
103	Genetic determinants of tissue factor pathway inhibitor plasma levels. Thrombosis and Haemostasis, 2015, 114, 245-257.	3.4	9
104	Chronic kidney disease has a significant impact on platelet inhibition of new P2Y12 inhibitors. International Journal of Cardiology, 2015, 184, 428-430.	1.7	7
105	Thrombin Generation Potential and Whole-Blood DNA methylation. Thrombosis Research, 2015, 135, 561-564.	1.7	7
106	Long-range epigenetic regulation is conferred by genetic variation located at thousands of independent loci. Nature Communications, 2015, 6, 6326.	12.8	115
107	Meta-analysis of 65,734 Individuals Identifies TSPAN15 and SLC44A2 as Two Susceptibility Loci for Venous Thromboembolism. American Journal of Human Genetics, 2015, 96, 532-542.	6.2	222
108	Theme 2: Epidemiology, Biomarkers, and Imaging of Venous Thromboembolism (and postthrombotic) Tj ETQq0 0 0 rgBT /Overlock 10 Tf	1.7	10

#	Article	IF	Citations
109	Genetic determined low response to thienopyridines is associated with higher systemic inflammation in smokers. Pharmacogenomics, 2015, 16, 459-469.	1.3	0
110	No Evidence for Genome-Wide Interactions on Plasma Fibrinogen by Smoking, Alcohol Consumption and Body Mass Index: Results from Meta-Analyses of 80,607 Subjects. PLoS ONE, 2014, 9, e111156.	2.5	8
111	Genome-Wide Association Study for Circulating Tissue Plasminogen Activator Levels and Functional Follow-Up Implicates Endothelial STXBP5 and STX2. Arteriosclerosis, Thrombosis, and Vascular Biology, 2014, 34, 1093-1101.	2.4	43
112	Robust validation of methylation levels association at CPT1A locus with lipid plasma levels. Journal of Lipid Research, 2014, 55, 1189-1191.	4.2	32
113	Risk assessment of venous thrombosis in families with known hereditary thrombophilia: the MARseillesâ€NImes prediction model. Journal of Thrombosis and Haemostasis, 2014, 12, 138-146.	3.8	17
114	Maximizing the Power of Principal-Component Analysis of Correlated Phenotypes in Genome-wide Association Studies. American Journal of Human Genetics, 2014, 94, 662-676.	6.2	149
115	Fixed-dose aspirinâ€“clopidogrel combination enhances compliance to aspirin after acute coronary syndrome. International Journal of Cardiology, 2014, 172, e1-e2.	1.7	13
116	DNA methylation and body-mass index: a genome-wide analysis. Lancet, The, 2014, 383, 1990-1998.	13.7	686
117	Impact of Obesity and the Metabolic Syndrome on Response to Clopidogrel or Prasugrel and Bleeding Risk in Patients Treated After Coronary Stenting. American Journal of Cardiology, 2014, 113, 54-59.	1.6	35
118	Multilocus Genetic Risk Scores for Venous Thromboembolism Risk Assessment. Journal of the American Heart Association, 2014, 3, e001060.	3.7	58
119	Economic Analysis Of Thrombo Incode, A Clinical-Genetic Function For Assessing The Risk Of Venous Thromboembolism. Value in Health, 2014, 17, A488.	0.3	0
120	Human CalDAG-GEFI gene (RASGRP2) mutation affects platelet function and causes severe bleeding. Journal of Experimental Medicine, 2014, 211, 1349-1362.	8.5	117
121	Effectiveness of switching â€˜low respondersâ€™ to prasugrel to ticagrelor after acute coronary syndrome. International Journal of Cardiology, 2014, 176, 1184-1185.	1.7	10
122	Influence of coronary artery disease-associated genetic variants on risk of venous thromboembolism. Thrombosis Research, 2014, 134, 426-432.	1.7	18
123	Body mass index has no impact on platelet inhibition induced by ticagrelor after acute coronary syndrome, conversely to prasugrel. International Journal of Cardiology, 2014, 176, 1200-1202.	1.7	21
124	Impact of new P2Y12 blockers on platelet reactivity and clinical outcomes after acute coronary syndrome: Insight from a large single center registry. International Journal of Cardiology Heart & Vessels, 2014, 4, 188-192.	0.5	4
125	Contribution of anti-Î²2glycoprotein I IgA antibodies to the diagnosis of anti-phospholipid syndrome: potential interest of target domains to discriminate thrombotic and non-thrombotic patients. Rheumatology, 2014, 53, 1215-1218.	1.9	30
126	A meta-analysis of genome-wide association studies identifies ORM1 as a novel gene controlling thrombin generation potential. Blood, 2014, 123, 777-785.	1.4	27

#	Article	IF	Citations
127	Genome-Wide Investigation of DNA Methylation Marks Associated with FV Leiden Mutation. PLoS ONE, 2014, 9, e108087.	2.5	7
128	First case of a humanRASGRP2mutation affecting Rap1 activation in platelets and causing severe bleeding.. Journal of Cell Biology, 2014, 206, 2061OIA111.	5.2	0
129	A genome-wide search for common SNP x SNP interactions on the risk of venous thrombosis. BMC Medical Genetics, 2013, 14, 36.	2.1	25
130	Clinical Implications of Very Low On-Treatment Platelet Reactivity in Patients Treated With Thienopyridine. JACC: Cardiovascular Interventions, 2013, 6, 854-863.	2.9	67
131	Prasugrel versus ticagrelor in acute coronary syndrome: A randomized comparison. International Journal of Cardiology, 2013, 170, e21-e22.	1.7	24
132	Predictors of long-term high on-treatment platelet reactivity in clopidogrel-treated patients undergoing coronary stenting for acute coronary syndrome. International Journal of Cardiology, 2013, 168, 1565-1566.	1.7	2
133	Platelet reactivity in diabetic patients undergoing coronary stenting for acute coronary syndrome treated with clopidogrel loading dose followed by prasugrel maintenance therapy. International Journal of Cardiology, 2013, 168, 523-528.	1.7	21
134	Effect of motivational mobile phone short message service on aspirin adherence after coronary stenting for acute coronary syndrome. International Journal of Cardiology, 2013, 168, 568-569.	1.7	65
135	A Genomeâ€Wide Association Study for Venous Thromboembolism: The Extended Cohorts for Heart and Aging Research in Genomic Epidemiology (CHARGE) Consortium. Genetic Epidemiology, 2013, 37, 512-521.	1.3	99
136	Management of cardiovascular disease in haemophilia. Thrombosis Research, 2013, 132, 8-14.	1.7	27
137	Effectiveness of switching â€˜hyper respondersâ€™ from Prasugrel to Clopidogrel after acute coronary syndrome: The POBA (Predictor of Bleeding with Antiplatelet drugs) SWITCH study. International Journal of Cardiology, 2013, 168, 5004-5005.	1.7	15
138	Off-label use of prasugrel in stable coronary artery disease is associated with greater degree of platelet inhibition compared with use after acute coronary syndrome. International Journal of Cardiology, 2013, 168, 2988-2989.	1.7	7
139	Anticoagulation with a new oral anticoagulant in heart transplant recipients. International Journal of Cardiology, 2013, 168, 4452-4453.	1.7	21
140	Prasugrel Monitoring and Bleeding in Real World Patients. American Journal of Cardiology, 2013, 111, 38-44.	1.6	41
141	Effect of CYP2C19*2 and *17 Genetic Variants on Platelet Response to Clopidogrel and Prasugrel Maintenance Dose and Relation to Bleeding Complications. American Journal of Cardiology, 2013, 111, 985-990.	1.6	59
142	Effectiveness of switching hyper responders from prasugrel to clopidogrel after acute coronary syndrome: the POBA SWITCH study. European Heart Journal, 2013, 34, P4883-P4883.	2.2	0
143	Clinical implications of very low on-treatment platelet reactivity in patients treated with thienopyridine: the POBA study (Predictor Of Bleedings with Antiplatelet drugs). European Heart Journal, 2013, 34, 4528-4528.	2.2	0
144	Multiple Biomarkers for the Prediction of Ischemic Stroke. Arteriosclerosis, Thrombosis, and Vascular Biology, 2013, 33, 659-666.	2.4	65

#	Article	IF	Citations
145	Multiethnic Meta-Analysis of Genome-Wide Association Studies in >100 000 Subjects Identifies 23 Fibrinogen-Associated Loci but No Strong Evidence of a Causal Association Between Circulating Fibrinogen and Cardiovascular Disease. Circulation, 2013, 128, 1310-1324.	1.6	128
146	Current knowledge on the genetics of incident venous thrombosis. Journal of Thrombosis and Haemostasis, 2013, 11, 111-121.	3.8	42
147	Impact of obesity on response to thienopyridine and bleeding risk in patients treated after acute coronary syndrome by clopidogrel or prasugrel. European Heart Journal, 2013, 34, P4878-P4878.	2.2	0
148	Thrombosis in central obesity and metabolic syndrome: Mechanisms and epidemiology. Thrombosis and Haemostasis, 2013, 110, 669-680.	3.4	121
149	Diet Modulates Endogenous Thrombin Generation, A Biological Estimate of Thrombosis Risk, Independently of the Metabolic Status. Arteriosclerosis, Thrombosis, and Vascular Biology, 2012, 32, 2394-2404.	2.4	26
150	Assessment of epicardial fat volume and myocardial triglyceride content in severely obese subjects: relationship to metabolic profile, cardiac function and visceral fat. International Journal of Obesity, 2012, 36, 422-430.	3.4	89
151	The endothelial protein C receptor (PROCR) Ser219Gly variant and risk of common thrombotic disorders: a HuGE review and meta-analysis of evidence from observational studies. Blood, 2012, 119, 2392-2400.	1.4	56
152	Apolipoprotein(a) Genetic Sequence Variants Associated With Systemic Atherosclerosis and Coronary Atherosclerotic Burden But Not With Venous Thromboembolism. Journal of the American College of Cardiology, 2012, 60, 722-729.	2.8	149
153	Lack of association of non-synonymous FUT2 and ALPL polymorphisms with venous thrombosis. Journal of Thrombosis and Haemostasis, 2012, 10, 1693-1695.	3.8	2
154	Genome-wide association study for circulating levels of PAI-1 provides novel insights into its regulation. Blood, 2012, 120, 4873-4881.	1.4	90
155	ABO Blood Group and von Willebrand Factor Levels Partially Explained the Incomplete Penetrance of Congenital Thrombophilia. Arteriosclerosis, Thrombosis, and Vascular Biology, 2012, 32, 2021-2028.	2.4	19
156	Genetic Associations for Activated Partial Thromboplastin Time and Prothrombin Time, their Gene Expression Profiles, and Risk of Coronary Artery Disease. American Journal of Human Genetics, 2012, 91, 152-162.	6.2	85
157	Association of soluble endothelial protein C receptor plasma levels and PROCR rs867186 with cardiovascular risk factors and cardiovascular events in coronary artery disease patients: The Athero Gene Study. BMC Medical Genetics, 2012, 13, 103.	2.1	17
158	Comparison between initial and chronic response to clopidogrel therapy after coronary stenting for acute coronary syndrome and influence on clinical outcomes. American Heart Journal, 2012, 164, 327-333.	2.7	8
159	CYP2C19*2 and *17 Alleles Have a Significant Impact on Platelet Response and Bleeding Risk in Patients Treated With Prasugrel After Acute Coronary Syndrome. JACC: Cardiovascular Interventions, 2012, 5, 1280-1287.	2.9	92
160	TFPI resistance related to inherited or acquired protein S deficiency. Thrombosis Research, 2012, 130, 925-928.	1.7	4
161	Genome wide association study for plasma levels of natural anticoagulant inhibitors and protein C anticoagulant pathway: the MARTHA project. British Journal of Haematology, 2012, 157, 230-239.	2.5	55
162	Recent advances in the pharmacogenetics of clopidogrel. Human Genetics, 2012, 131, 653-664.	3.8	26

#	Article	IF	Citations
163	Genetic variation in F3 (tissue factor) and the risk of incident venous thrombosis: metaâ€analysis of eight studies. Journal of Thrombosis and Haemostasis, 2012, 10, 719-722.	3.8	8
164	Caution in Interpreting Results from Imputation Analysis When Linkage Disequilibrium Extends over a Large Distance: A Case Study on Venous Thrombosis. PLoS ONE, 2012, 7, e38538.	2.5	17
165	miR-421 and miR-30c Inhibit SERPINE 1 Gene Expression in Human Endothelial Cells. PLoS ONE, 2012, 7, e44532.	2.5	56
166	Paraoxonase-1 and clopidogrel efficacy. Nature Medicine, 2011, 17, 1039-1039.	30.7	27
167	Effects of insulin-like growth factor 1 in preventing acute coronary syndromes: The PRIME study. Atherosclerosis, 2011, 218, 464-469.	0.8	43
168	The natural occurrence of human fibrinogen variants disrupting inter-chain disulfide bonds (AÂCys36Gly, AÂCys36Arg and AÂCys45Tyr) confirms the role of N-terminal AÂ disulfide bonds in protein assembly and secretion. Haematologica, 2011, 96, 1226-1230.	3.5	11
169	Prevalence and epitope specificity of non-neutralising antibodies in a large cohort of haemophilia A patients without inhibitors. Thrombosis and Haemostasis, 2011, 105, 954-961.	3.4	28
170	Association of vitronectin and plasminogen activator inhibitor-1 levels with the risk of metabolic syndrome and type 2 diabetes mellitus. Thrombosis and Haemostasis, 2011, 106, 416-422.	3.4	34
171	KNG1 Ile581Thr and susceptibility to venous thrombosis. Blood, 2011, 117, 3692-3694.	1.4	53
172	Impact on venous thrombosis risk of newly discovered gene variants associated with FVIII and VWF plasma levels. Journal of Thrombosis and Haemostasis, 2011, 9, 229-231.	3.8	20
173	CD11b+ leukocyte microparticles are associated with highâ€risk angiographic lesions and recurrent cardiovascular events in acute coronary syndromes. Journal of Thrombosis and Haemostasis, 2011, 9, 1870-1873.	3.8	16
174	Lessons from genomeâ€wide association studies in venous thrombosis. Journal of Thrombosis and Haemostasis, 2011, 9, 258-264.	3.8	36
175	Usefulness of High Clopidogrel Maintenance Dose According to CYP2C19 Genotypes in Clopidogrel Low Responders Undergoing Coronary Stenting for Non ST Elevation Acute Coronary Syndrome. American Journal of Cardiology, 2011, 108, 760-765.	1.6	40
176	Comparison of Platelet Reactivity and Clopidogrel Response in Patients â‰¥75 Years Versus >75 Years Undergoing Percutaneous Coronary Intervention for Nonâ€“ST-Segment Elevation Acute Coronary Syndrome. American Journal of Cardiology, 2011, 108, 1411-1416.	1.6	18
177	Combined analysis of three genome-wide association studies on vWF and FVIII plasma levels. BMC Medical Genetics, 2011, 12, 102.	2.1	63
178	High prevalence of laminopathies among patients with metabolic syndrome. Human Molecular Genetics, 2011, 20, 3779-3786.	2.9	58
179	High Residual Platelet Reactivity and Thrombotic Events. JAMA - Journal of the American Medical Association, 2011, 306, 2561-2561.	7.4	1
180	The Factor XII â^'4C>T Variant and Risk of Common Thrombotic Disorders: A HuGE Review and Meta-Analysis of Evidence From Observational Studies. American Journal of Epidemiology, 2011, 173, 136-144.	3.4	21

#	Article	IF	Citations
181	Systemic chemokine levels, coronary heart disease, and ischemic stroke events. Neurology, 2011, 77, 1165-1173.	1.1	55
182	Circulating Matrix Metalloproteinases in Infective Endocarditis: A Possible Marker of the Embolic Risk. PLoS ONE, 2011, 6, e18830.	2.5	18
183	Genetics of Venous Thrombosis: Insights from a New Genome Wide Association Study. PLoS ONE, 2011, 6, e25581.	2.5	127
184	Mesopic vision characteristics at decreased contrast in fog. Proceedings of SPIE, 2010, , .	0.8	0
185	C4BPB/C4BPA is a new susceptibility locus for venous thrombosis with unknown protein Sâ€“independent mechanism: results from genome-wide association and gene expression analyses followed by case-control studies. Blood, 2010, 115, 4644-4650.	1.4	61
186	A Follow-Up Study of a Genome-wide Association Scan Identifies a Susceptibility Locus for Venous Thrombosis on Chromosome 6p24.1. American Journal of Human Genetics, 2010, 86, 592-595.	6.2	57
187	A Follow-Up Study of a Genome-wide Association Scan Identifies a Susceptibility Locus for Venous Thrombosis on Chromosome 6p24.1. American Journal of Human Genetics, 2010, 86, 655.	6.2	0
188	Polymorphisms of the lamina maturation pathway and their association with the metabolic syndrome: the DESIR prospective study. Journal of Molecular Medicine, 2010, 88, 193-201.	3.9	5
189	Prothrombin G20210A carriers the genetic mutation and a history of venous thrombosis contributes to thrombin generation independently of factor II plasma levels. Journal of Thrombosis and Haemostasis, 2010, 8, 942-949.	3.8	17
190	Protein S inherited qualitative deficiency: novel mutations and phenotypic influence. Journal of Thrombosis and Haemostasis, 2010, 8, 2718-2726.	3.8	19
191	A multiâ€stage multiâ€design strategy provides strong evidence that the BAI3 locus is associated with earlyâ€onset venous thromboembolism. Journal of Thrombosis and Haemostasis, 2010, 8, 2671-2679.	3.8	42
192	Deciphering the molecular basis of venous thromboembolism: where are we and where should we go?. British Journal of Haematology, 2010, 148, 495-506.	2.5	14
193	Adipocytokines and the risk of coronary heart disease in healthy middle aged men: the PRIME Study. International Journal of Obesity, 2010, 34, 118-126.	3.4	45
194	Les facteurs deÂrisque gÃ©nÃ©tique deÂlaÂthrombose veineuse: oÃ¹ÂenÂsommes nous?. Sang Thrombose Vaisseaux, 2010, 22, 421-427.	0.1	0
195	Relative Contribution of Lipids and Apolipoproteins to Incident Coronary Heart Disease and Ischemic Stroke: The PRIME Study. Cerebrovascular Diseases, 2010, 30, 252-259.	1.7	52
196	C-Reactive Protein, Interleukin 6, Fibrinogen and Risk of Sudden Death in European Middle-Aged Men: The PRIME Study. Arteriosclerosis, Thrombosis, and Vascular Biology, 2010, 30, 2047-2052.	2.4	96
197	Clopidogrel response: Head-to-head comparison of different platelet assays to identify clopidogrel non responder patients after coronary stenting. Archives of Cardiovascular Diseases, 2010, 103, 39-45.	1.6	53
198	Clinical characteristics and laboratory testing of patients with suspected HIT: A survey on current practice in 11 university hospitals in France. Thrombosis Research, 2010, 125, e294-e299.	1.7	9

#	Article	IF	Citations
199	Comparison of rosuvastatin and atorvastatin on clopidogrel response and lipidic and inflammatory parameters after coronary stenting for acute coronary syndrome: The prospective, randomized OSCAR study (optimal statin therapy with clopidogrel after coronary revascularisation). Thrombosis Research, 2010, 126, e397-e399.	1.7	3
200	Lack of effect of chronic kidney disease on clopidogrel response with high loading and maintenance doses of clopidogrel after Acute Coronary Syndrome. Thrombosis Research, 2010, 126, e400-e402.	1.7	24
201	Respective contribution of conventional risk factors and antihypertensive treatment to stable angina pectoris and acute coronary syndrome as the first presentation of coronary heart disease: the PRIME Study. European Journal of Cardiovascular Prevention and Rehabilitation, 2009, 16, 550-555.	2.8	4
202	Common susceptibility alleles are unlikely to contribute as strongly as the FV and ABO loci to VTE risk: results from a GWAS approach. Blood, 2009, 113, 5298-5303.	1.4	283
203	Factor V Leiden Homozygous Genotype and Pregnancy Outcomes. Obstetrics and Gynecology, 2009, 114, 1249-1253.	2.4	10
204	Predictive Values of Post-Treatment Adenosine Diphosphateâ€“Induced Aggregation and Vasodilator-Stimulated Phosphoprotein Index for Stent Thrombosis After Acute Coronary Syndrome in Clopidogrel-Treated Patients. American Journal of Cardiology, 2009, 104, 1078-1082.	1.6	66
205	On the use of phylogenyâ€based tests to detect association between quantitative traits and haplotypes. Genetic Epidemiology, 2009, 33, 729-739.	1.3	7
206	Activated thrombin activatable fibrinolysis inhibitor levels are associated with the risk of cardiovascular death in patients with coronary artery disease: the AtheroGene study. Journal of Thrombosis and Haemostasis, 2009, 7, 49-57.	3.8	169
207	Relationship between aspirin and clopidogrel responses in acute coronary syndrome and clinical predictors of non response. Thrombosis Research, 2009, 123, 597-603.	1.7	72
208	Effect of increased aspirin dose after Stenting in association with ClOpidogrel: The FIASCO randomized study. Thrombosis Research, 2009, 124, 33-36.	1.7	2
209	Aspirin noncompliance is the major cause of â€œaspirin resistanceâ€•in patients undergoing coronary stenting. American Heart Journal, 2009, 157, 889-893.	2.7	78
210	Comparison of Omeprazole and Pantoprazole Influence on a High 150-mg Clopidogrel Maintenance Dose. Journal of the American College of Cardiology, 2009, 54, 1149-1153.	2.8	212
211	Recommendations on Testing for Thrombophilia in Venous Thromboembolic Disease: a French Consensus Guideline. Journal Des Maladies Vasculaires, 2009, 34, 156-203.	0.6	89
212	Molecular characterization of a novel mutation in the factor XIII a subunit gene associated with a severe defect: importance of prophylactic substitution. Blood Coagulation and Fibrinolysis, 2009, 20, 605-606.	1.0	6
213	Prospective analysis of factor XI deficiencies in the Marseilles area identified four novel mutations among 12 consecutive unrelated families. Blood Coagulation and Fibrinolysis, 2009, 20, 84-88.	1.0	6
214	Predictive value of post-treatment platelet reactivity for occurrence of post-discharge bleeding after non-ST elevation acute coronary syndrome.. EuroIntervention, 2009, 5, 325-329.	3.2	123
215	Glycoprotein IIb/IIIa Inhibitors Improve Outcome After Coronary Stenting in Clopidogrel Nonresponders. JACC: Cardiovascular Interventions, 2008, 1, 649-653.	2.9	140
216	Polymorphisms of the tumor necrosis factor-alpha (TNF) and the TNF-alpha converting enzyme (TACE/ADAM17) genes in relation to cardiovascular mortality: the AtheroGene study. Journal of Molecular Medicine, 2008, 86, 1153-1161.	3.9	44

#	Article	IF	Citations
217	Relation between the antithrombin Cambridge II mutation, the risk of venous thrombosis, and the endogenous thrombin generation. Journal of Thrombosis and Haemostasis, 2008, 6, 1975-1977.	3.8	13
218	Effect of Cytochrome P450 Polymorphisms on Platelet Reactivity After Treatment With Clopidogrel in Acute Coronary Syndrome. American Journal of Cardiology, 2008, 101, 1088-1093.	1.6	194
219	Aprotinin Administration and Pulmonary Embolism After Aortic Valve Replacement. Journal of Cardiothoracic and Vascular Anesthesia, 2008, 22, 255-258.	1.3	0
220	Contribution of novel biomarkers to incident stable angina and acute coronary syndrome: the PRIME Study. European Heart Journal, 2008, 29, 1966-1974.	2.2	53
221	The Poly(ADP-ribose) Polymerase PARP-1 Is Required for Oxidative Stress-induced TRPM2 Activation in Lymphocytes. Journal of Biological Chemistry, 2008, 283, 24571-24583.	3.4	131
222	Association of Plasminogen Activator Inhibitor (PAI)-1 (SERPINE1) SNPs With Myocardial Infarction, Plasma PAI-1, and Metabolic Parameters. Arteriosclerosis, Thrombosis, and Vascular Biology, 2007, 27, 2250-2257.	2.4	65
223	Role of the T744C polymorphism of the P2Y12 gene on platelet response to a 600-mg loading dose of clopidogrel in 597 patients with non-ST-segment elevation acute coronary syndrome. Thrombosis Research, 2007, 120, 893-899.	1.7	77
224	High post-treatment platelet reactivity is associated with a high incidence of myonecrosis after stenting for non-ST elevation acute coronary syndromes. Thrombosis and Haemostasis, 2007, 97, 282-287.	3.4	102
225	Lack of association between the 807 C/T polymorphism of glycoprotein Ia gene and post-treatment platelet reactivity after aspirin and clopidogrel in patients with acute coronary syndrome. Thrombosis and Haemostasis, 2007, 97, 212-217.	3.4	67
226	ADP-induced platelet aggregation and platelet reactivity index VASP are good predictive markers for clinical outcomes in non-ST elevation acute coronary syndrome. Thrombosis and Haemostasis, 2007, 98, 838-843.	3.4	203
227	Molecular characterization of a novel mutation in the factor XIII A subunit gene associated with a severe defect and an adulthood diagnosis. Haemophilia, 2007, 13, 221-222.	2.1	8
228	Prognostic value of plasma tissue factor and tissue factor pathway inhibitor for cardiovascular death in patients with coronary artery disease: the AtheroGene study. Journal of Thrombosis and Haemostasis, 2007, 5, 475-482.	3.8	68
229	Polymorphism A36G of the tumor necrosis factor receptor 1 gene is associated with PAI-1 levels in obese women. Thrombosis and Haemostasis, 2007, 97, 62-66.	3.4	10
230	Lack of association between the 807 C/T polymorphism of glycoprotein Ia gene and post-treatment platelet reactivity after aspirin and clopidogrel in patients with acute coronary syndrome. Thrombosis and Haemostasis, 2007, 97, 212-7.	3.4	5
231	Benefit of a 600-mg Loading Dose of Clopidogrel on Platelet Reactivity and Clinical Outcomes in Patients With Nonâ€“ST-Segment Elevation Acute Coronary Syndrome Undergoing Coronary Stenting. Journal of the American College of Cardiology, 2006, 48, 1339-1345.	2.8	329
232	Fine mapping of quantitative trait nucleotides underlying thrombin-activatable fibrinolysis inhibitor antigen levels by a transethnic study. Blood, 2006, 108, 1562-1568.	1.4	37
233	Predictive factors for thrombosis and major bleeding in an observational study in 181 patients with heparin-induced thrombocytopenia treated with lepirudin. Blood, 2006, 108, 1492-1496.	1.4	103
234	High postâ€treatment platelet reactivity identified lowâ€responders to dual antiplatelet therapy at increased risk of recurrent cardiovascular events after stenting for acute coronary syndrome. Journal of Thrombosis and Haemostasis, 2006, 4, 542-549.	3.8	349

#	Article	IF	Citations
235	ABO blood group but not haemostasis genetic polymorphisms significantly influence thrombotic risk: a study of 180 homozygotes for the Factor V Leiden mutation. British Journal of Haematology, 2006, 135, 697-702.	2.5	23
236	Haemostatic Factors and the Risk of Cardiovascular Death in Patients With Coronary Artery Disease. Arteriosclerosis, Thrombosis, and Vascular Biology, 2006, 26, 2793-2799.	2.4	96
237	TAFI gene haplotypes, TAFI plasma levels and future risk of coronary heart disease: the PRIME Study. Journal of Thrombosis and Haemostasis, 2005, 3, 1503-1510.	3.8	55
238	Biological and genetic factors influencing plasma factor VIII levels in a healthy family population: results from the Stanislas cohort. British Journal of Haematology, 2005, 128, 91-99.	2.5	80
239	Quantification of thrombin activatable fibrinolysis inhibitor (TAFI) gene polymorphism effects on plasma levels of TAFI measured with assays insensitive to isoform-dependent artefact. Thrombosis and Haemostasis, 2005, 94, 373-9.	3.4	34
240	Interaction between the C-260T polymorphism of the CD14 gene and the plasma IL-6 concentration on the risk of myocardial infarction: the HIFMECH study. Atherosclerosis, 2005, 179, 317-323.	0.8	25
241	Juvenile temporal arteritis and activated protein C resistance. Annals of the Rheumatic Diseases, 2004, 63, 215-216.	0.9	9
242	Association Between Factor VII Polymorphisms and Blood Pressure. Hypertension, 2004, 44, 674-680.	2.7	8
243	Endothelial Cell Markers and the Risk of Coronary Heart Disease. Circulation, 2004, 109, 1343-1348.	1.6	203
244	Protein Z plasma levels are not associated with the risk of coronary heart disease: the PRIME Study. Journal of Thrombosis and Haemostasis, 2004, 2, 2050-2051.	3.8	22
245	Risk of venous thromboembolism during pregnancy in homozygous carriers of the factor V Leiden mutation: are there any predictive factors?. Journal of Thrombosis and Haemostasis, 2004, 2, 359-360.	3.8	7
246	TLR4/Asp299Gly, CD14/C-260T, plasma levels of the soluble receptor CD14 and the risk of coronary heart disease: The PRIME Study. European Journal of Human Genetics, 2004, 12, 1041-1049.	2.8	71
247	Low-grade inflammation may play a role in the etiology of the metabolic syndrome in patients with coronary heart disease: the HIFMECH study. Metabolism: Clinical and Experimental, 2004, 53, 852-857.	3.4	137
248	Exclusive expression of transmembrane TNF-Î± in mice reduces the inflammatory response in early lipid lesions of aortic sinus. Atherosclerosis, 2004, 172, 211-218.	0.8	87
249	Relations between hemostatic variables, insulin resistance and inflammation. The Hematology Journal, 2004, 5, S15-S19.	1.4	2
250	Weak and non-independent association between plasma TAFI antigen levels and the insulin resistance syndrome. Journal of Thrombosis and Haemostasis, 2003, 1, 791-797.	3.8	55
251	Plasminogen activator inhibitor-1, inflammation, obesity, insulin resistance and vascular risk. Journal of Thrombosis and Haemostasis, 2003, 1, 1575-1579.	3.8	315
252	Very high TAFI antigen levels are associated with a lower risk of hard coronary events: the PRIME Study. Journal of Thrombosis and Haemostasis, 2003, 1, 2243-2244.	3.8	35

#	Article	IF	Citations
253	The plasminogen activator inhibitor-1 -675 4G/5G genotype influences the risk of myocardial infarction associated with elevated plasma proinsulin and insulin concentrations in men from Europe: the HIFMECH Study. Journal of Thrombosis and Haemostasis, 2003, 1, 2322-2329.	3.8	52
254	Venous thromboembolism in asymptomatic carriers of factor V Leiden mutation from symptomatic families: any role for hormonal replacement treatment?. Journal of Thrombosis and Haemostasis, 2003, 1, 1325-1326.	3.8	0
255	Nutritionally Induced Obesity Is Attenuated in Transgenic Mice Overexpressing Plasminogen Activator Inhibitor-1. Arteriosclerosis, Thrombosis, and Vascular Biology, 2003, 23, 78-84.	2.4	91
256	Plasma PAI-1 Levels Are More Strongly Related to Liver Steatosis Than to Adipose Tissue Accumulation. Arteriosclerosis, Thrombosis, and Vascular Biology, 2003, 23, 1262-1268.	2.4	168
257	Association between TAFI antigen and Ala147Thr polymorphism of the TAFI gene and the angina pectoris incidence. Thrombosis and Haemostasis, 2003, 89, 554-560.	3.4	65
258	Stromal Cells Are the Main Plasminogen Activator Inhibitor-1-Producing Cells in Human Fat. Arteriosclerosis, Thrombosis, and Vascular Biology, 2002, 22, 173-178.	2.4	182
259	Thr325Ile polymorphism of the TAFI gene does not influence the risk of myocardial infarction. Blood, 2002, 99, 1878-1878.	1.4	21
260	The insulin resistance syndrome: implications for thrombosis and cardiovascular disease. Pathophysiology of Haemostasis and Thrombosis: International Journal on Haemostasis and Thrombosis Research, 2002, 32, 269-273.	0.3	60
261	Plasma Thrombin-Activatable Fibrinolysis Inhibitor Antigen Concentration and Genotype in Relation to Myocardial Infarction in the North and South of Europe. Arteriosclerosis, Thrombosis, and Vascular Biology, 2002, 22, 867-873.	2.4	137
262	Influence of t-PA and u-PA on Adipose Tissue Development in a Murine Model of Diet-Induced Obesity. Thrombosis and Haemostasis, 2002, 87, 306-310.	3.4	28
263	Ala147Thr and C+1542G Polymorphisms in the TAFI Gene Are not Asssociated with a Higher Risk of Venous Thrombosis in FV Leiden Carriers. Thrombosis and Haemostasis, 2001, 86, 1583-1584.	3.4	16
264	Adipose Tissue Expression of Gelatinases in Mouse Models of Obesity. Thrombosis and Haemostasis, 2001, 85, 1111-1116.	3.4	61
265	Plasma Levels of Free and Total TFPI, Relationship with Cardiovascular Risk Factors and Endothelial Cell Markers. Thrombosis and Haemostasis, 2001, 85, 999-1003.	3.4	38
266	Factor XIIIV34L is not an additional genetic risk factor for venous thrombosis in Factor V Leiden carriers. Blood, 2001, 97, 1894-1896.	1.4	6
267	Identification of polymorphisms in the promoter and the 3â€² region of the TAFI gene: evidence that plasma TAFI antigen levels are strongly genetically controlled. Blood, 2001, 97, 2053-2058.	1.4	140
268	Comparison of thrombotic risk between 85 homozygotes and 481 heterozygotes carriers of the factor V Leiden mutation: retrospective analysis from the Procare Study. Blood Coagulation and Fibrinolysis, 2000, 11, 511-518.	1.0	21
269	Acquired inhibitor of thrombin associated with an ulcerative colitis. American Journal of Hematology, 2000, 64, 322-322.	4.1	1
270	Plasma TAFI Antigen Variations in Healthy Subjects. Thrombosis and Haemostasis, 2000, 83, 902-905.	3.4	99

#	Article	IF	Citations
271	Genetic Polymorphisms and Coronary Artery Disease in the South of France. Thrombosis and Haemostasis, 2000, 83, 212-216.	3.4	98
272	The A â˜’844G Polymorphism in the PAI-1 Gene Is Associated With a Higher Risk of Venous Thrombosis in Factor V Leiden Carriers. Arteriosclerosis, Thrombosis, and Vascular Biology, 2000, 20, 1387-1391.	2.4	55
273	Fat Cell Function and Fibrinolysis. Hormone and Metabolic Research, 2000, 32, 504-508.	1.5	45
274	Plasminogen activator inhibitor 1, transforming growth factor-beta1, and BMI are closely associated in human adipose tissue during morbid obesity. Diabetes, 2000, 49, 1374-1380.	0.6	322
275	Thrombin-Activatable Fibrinolysis Inhibitor Antigen Levels and Cardiovascular Risk Factors. Arteriosclerosis, Thrombosis, and Vascular Biology, 2000, 20, 2156-2161.	2.4	86
276	Influence of PAI-1 on Adipose Tissue Growth and Metabolic Parameters in a Murine Model of Diet-Induced Obesity. Arteriosclerosis, Thrombosis, and Vascular Biology, 2000, 20, 1150-1154.	2.4	124
277	Rapid Detection of Factor XIII Val34Leu by Allele Specific PCR. Thrombosis and Haemostasis, 1999, 81, 463-463.	3.4	13
278	PAI-1 Produced Ex Vivo by Human Adipose Tissue Is Relevant to PAI-1 Blood Level. Arteriosclerosis, Thrombosis, and Vascular Biology, 1999, 19, 1361-1365.	2.4	99
279	Catastrophic Arterial Reactivity During Primary Antiphospholipid Syndrome. Angiology, 1999, 50, 761-764.	1.8	2
280	Fibrinolytic function and coronary risk. Current Cardiology Reports, 1999, 1, 119-124.	2.9	28
281	Glucocorticoids and insulin promote plasminogen activator inhibitor 1 production by human adipose tissue.. Diabetes, 1999, 48, 890-895.	0.6	117
282	Regulation of PAI-1 in obesity and insulin resistance. Atherosclerosis, 1999, 144, 14.	0.8	0
283	Screening for Identified and Unidentified Protein C Pathway Defects by theAgkistrodon contortrixVenom Test in Consecutive Patients. American Journal of Clinical Pathology, 1999, 112, 233-237.	0.7	6
284	Relationship of Plasminogen Activator Inhibitor-1 Levels following Thrombolytic Therapy with rt-PA as Compared to Streptokinase and Patency of Infarct Related Coronary Artery. Thrombosis and Haemostasis, 1999, 82, 104-108.	3.4	22
285	Effect of weight change and metformin on fibrinolysis and the von Willebrand factor in obese nondiabetic subjects: the BIGPRO1 Study. Biguanides and the Prevention of the Risk of Obesity.. Diabetes Care, 1998, 21, 1967-1972.	8.6	120
286	A Three-generation Family Presenting Five Cases of Homozygosity for the 20210 G to A Prothrombin Variant. Thrombosis and Haemostasis, 1998, 80, 859-860.	3.4	14
287	Acquired Protein S Deficiency, Likely due to Anti-PS Autoantibodies, following a Thrombotic Event in a Patient with a Systemic Lupus erythematosus. Thrombosis and Haemostasis, 1997, 78, 1416-1417.	3.4	12
288	Production of plasminogen activator inhibitor 1 by human adipose tissue: possible link between visceral fat accumulation and vascular disease. Diabetes, 1997, 46, 860-867.	0.6	175